查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947958

銀屑病IL-17抑制劑市場：按產品、適應症、分銷管道、最終用戶、治療方法、給藥頻率和患者類型分類的全球預測（2026-2032年）

IL-17 Inhibitors for Psoriasis Market by Product, Indication, Distribution Channel, End User, Therapeutic Regimen, Dosing Frequency, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，用於治療乾癬的 IL-17 抑制劑市場價值將達到 23.3 億美元，到 2026 年將成長至 24.6 億美元，複合年成長率為 5.86%，到 ​​2032 年將達到 34.8 億美元。

關鍵市場統計數據
基準年 2025 23.3億美元
預計年份：2026年 24.6億美元
預測年份 2032 34.8億美元
複合年成長率 (%) 5.86%

為IL-17抑制劑在皮膚病學和風濕病學治療路徑中的應用，以及在各種醫療保健機構中的應用，提供臨床、商業性和營運方面的背景資訊。

IL-17抑制劑類藥物重新定義了免疫介導性皮膚病的治療方法，為中重度斑塊型乾癬及伴隨乾癬性關節炎患者提供了強效的標靶標靶治療選擇。本文回顧了目前治療策略的機制原理、臨床定位和商業性趨勢。透過聚焦於直接調節IL-17通路的藥物，臨床醫生現在擁有了一種新的選擇，該選擇能夠快速改善皮膚症狀，提供持久的療效，並可實現差異化的給藥方案，從而提高患者的依從性並促進其與醫療保健系統的整合。

關鍵的臨床、監管和商業性轉折點將重塑IL-17療法在現代醫療保健環境中的應用及其在競爭格局中的定位。

IL-17抑制劑領域正經歷變革性的轉變，這主要得益於臨床的成熟、監管的演變以及商業性創新。在臨床方面，越來越多的證據表明其具有長期療效、安全性和真實世界有效性，從而最佳化了患者選擇和治療順序。這促成了更精細的治療路徑，優先考慮針對重症患者或需要快速控制病情患者的速效藥物，以及兼顧給藥便利性和安全性的維持治療策略。

預計美國在2025年將進行的關稅調整將對IL-17療法的生物製藥供應鏈、定價動態和市場進入策略造成動態。

美國計劃於2025年調整關稅，將為生物製藥供應鏈帶來新的複雜性，影響原料、原料藥藥物成分的採購以及跨境生產的經濟效益。依賴進口國際原料和成品的製造商將面臨到岸成本的重新調整，這可能導致與供應商和物流合作夥伴重新談判合約。為此，供應鏈領導者正在重新評估供應商多元化、近岸外包能力和庫存策略，以降低進口關稅上漲的風險。

基於深度細分的智慧分析揭示了驅動市場動態的產品、適應症、通路、最終用戶、治療方法、劑量和患者群體動態。

細分市場分析揭示了不同產品、適應症、管道、終端用戶、治療方法、給藥頻率和患者群體之間存在的顯著商業性和臨床動態差異，這些差異影響著治療定位和營運重點。在比較Brodalumab、ixekizumab 和 sectinimab 等藥物時，其作用機制、起效時間和適應症範圍的細微差別會影響處方醫生的偏好和生命週期策略。適應症的具體考慮導致斑塊型乾癬和乾癬性關節炎的用藥存在差異，而關節受累則需要與風濕病學診療路徑合作以及多學科診療協調。

全面的區域觀點，重點在於美洲、歐洲、中東和非洲以及亞太地區的准入、監管和供應的重要性。

區域趨勢將對IL-17抑制劑的臨床實踐、監管方法和商業策略產生深遠影響。在美洲，完善的支付方體系、成熟的專科藥房生態系統以及臨床醫生對藥物的積極採納，共同營造了一種環境，既能促進新型療法的快速應用，又能確保支付方進行嚴格的審核，並協商確定准入途徑。市場參與企業致力於證明藥物價值、產生療效數據，並建構支持長期用藥依從性的整合式醫療模式。

為了保持 IL-17 抑制劑業務的強大基礎，製造商們正在採取策略性的企業方法，強調臨床差異化、生命週期延長和生態系統合作。

IL-17抑制劑領域的主要企業正在臨床開發、生命週期管理和商業營運等各個環節實施差異化策略。擁有成熟產品的製造商正致力於透過長期療效研究、安全性監測計畫以及頭對頭或真實世界對比分析來提升產品的臨床價值。這些努力有助於處方集繼續納入藥品目錄，並與支付方進行談判，同時也有助於產品被納入指南和獲得專業學會的推薦。

製造商和相關人員在確保獲得IL-17療法、增強供應韌性和促進持續應用方面面臨的實際策略挑戰

在不斷變化的市場動態中，產業領導者應採取一系列綜合措施，以保障患者用藥、最佳化商業性績效並強化供應鏈。首先，應投資於強力的真實世界證據項目，量化皮膚科和風濕病科的治療效果、安全性和依從性，從而支持與支付方和醫療系統開展基於價值的對話。結合藥物經濟模型和病患報告結局，這將有助於提升藥物在藥品目錄上的排名，並增強醫保報銷談判的籌碼。

一項透明的混合方法研究框架，結合系統性回顧、專家訪談和資料檢驗，旨在產生可操作的IL-17抑制劑見解。

本研究採用混合方法，結合系統性文獻回顧、有針對性的初步研究以及專家訪談三角驗證，以確保分析的嚴謹性。證據基礎包括同行評審的臨床試驗、監管申報文件、指南聲明以及真實世界觀察性研究，旨在捕捉不同治療環境下的療效、安全性和使用模式。初步研究包括對皮膚科和風濕科的關鍵管理人員、供應鏈管理人員、專科藥房營運人員以及支付方代表進行結構化訪談，以將臨床發現與實際營運情況聯繫起來。

這份簡明扼要、綜合全面的分析報告重點闡述了臨床差異化、供應韌性和適應性商業模式三者之間的交集，這些因素將決定IL-17療法的長期成功。

總之，IL-17抑制劑是治療層級在斑塊型乾癬和乾癬性關節炎治療中日益成熟的重要治療藥物，在提供顯著臨床效益的同時，也面臨著運作和商業上的複雜性。適應症、患者群體和給藥方案的不斷演變，要求我們採取積極主動的生命週期管理、重點開展循證研究以及製定以治療連續性為優先的適應性分銷策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 乾癬IL-17抑制劑市場（依產品分類）

  • Brodalumab
  • 伊克珠單抗
  • 塞克替尼單抗

9. IL-17抑制劑在乾癬治療的市場（依適應症分類）

  • 斑塊型乾癬
  • 乾癬性關節炎

10. 銀屑病IL-17抑制劑市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 鏈
    • 獨立的

11. 銀屑病IL-17抑制劑市場（依最終用戶分類）

  • 居家醫療環境
  • 醫院
  • 專科診所

12. IL-17抑制劑在乾癬治療中的市場（依治療方法）

  • 聯合治療
    • Cyclosporine
    • 胺基甲基葉酸
  • 單藥治療

13. 依給藥頻率分類的用於治療乾癬的IL-17抑制劑市場

  • 每隔一周
  • 每月一次

14. 乾癬IL-17抑制劑市場（依患者類型分類）

  • 成人
  • 小兒科
    • 青春期
    • 兒童

15. 各地區乾癬IL-17抑制劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

16. 銀屑病IL-17抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 各國銀屑病IL-17抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

18. 美國用於治療乾癬的IL-17抑制劑市場

19. 中國：用於治療乾癬的IL-17抑制劑市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Almirall, SA
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galderma SA
  • Johnson & Johnson
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Valeant Pharmaceuticals International, Inc.
Product Code: MRR-4F7A6D4FB6A8

The IL-17 Inhibitors for Psoriasis Market was valued at USD 2.33 billion in 2025 and is projected to grow to USD 2.46 billion in 2026, with a CAGR of 5.86%, reaching USD 3.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.33 billion
Estimated Year [2026] USD 2.46 billion
Forecast Year [2032] USD 3.48 billion
CAGR (%) 5.86%

Framing the clinical, commercial, and operational context for IL-17 inhibitors in dermatology and rheumatology treatment pathways across care settings

The IL-17 inhibitor class has redefined therapeutic approaches for immune-mediated skin disease, delivering potent pathway-targeted options for patients with moderate to severe plaque psoriasis and for those with concomitant psoriatic arthritis. This introduction summarizes the mechanistic rationale, clinical positioning, and commercial dynamics that underpin current treatment strategies. By focusing on agents that directly modulate the IL-17 axis, clinicians have gained alternatives that offer rapid skin clearance, durable responses, and differentiated dosing regimens that influence adherence and health system integration.

Across treatment settings, payers and providers are balancing clinical benefits against safety profiles, long-term data, and total cost of care. The interplay between monotherapy and combination regimens, the expansion of dosing frequency options, and the growing consideration of pediatric populations are reshaping prescribing algorithms. Simultaneously, distribution and access pathways-from hospital formularies to online specialty pharmacies and community retail networks-are evolving to support diverse end users, including home care and specialty clinic models.

This introduction sets the stage for a deeper analysis by highlighting the class's therapeutic strengths, the operational levers that affect uptake, and the strategic inflection points that stakeholders should monitor. Subsequent sections examine structural market shifts, tariff and supply chain influences, segmentation-driven insights, and practical actions leaders can take to optimize patient outcomes and commercial performance.

Critical clinical, regulatory, and commercial inflection points reshaping adoption and competitive positioning of IL-17 therapies in contemporary care environments

The IL-17 inhibitor landscape is undergoing transformative shifts driven by clinical maturation, regulatory evolution, and commercial innovation. On the clinical front, expanding evidence on long-term efficacy, safety, and real-world effectiveness is refining patient selection and sequencing decisions. This has led to more nuanced treatment pathways where rapid onset agents are prioritized for severe cases or those requiring swift disease control, while dosing convenience and safety profiles inform maintenance strategies.

Regulatory and label developments have broadened the addressable patient population, prompting manufacturers to reassess orphan and pediatric strategies as appropriate. Commercially, the introduction of flexible distribution models-including enhanced specialty pharmacy programs and direct-to-patient support-has altered how therapies are delivered and supported. These changes are reinforced by payer policies that increasingly emphasize outcomes, step therapy exceptions for high clinical need, and value-based contracting pilots that tie reimbursement to real-world results.

Product lifecycle management is another major vector of change. Biologics manufacturers are optimizing dosing regimens, exploring combination approaches with conventional systemic agents, and investing in patient support infrastructure to sustain adherence. In parallel, competitors are differentiating through device innovation, user experience, and digital therapeutics that complement biologic treatment. Taken together, these shifts create a dynamic environment in which clinical differentiation, supply reliability, and adaptive commercial models determine competitive success.

How anticipated 2025 tariff shifts in the United States will pressure biologics supply chains, pricing dynamics, and market access strategies for IL-17 therapies

Projected tariff adjustments in the United States for 2025 introduce a new layer of complexity for biologics supply chains, affecting raw materials, active pharmaceutical ingredient sourcing, and cross-border manufacturing economics. Manufacturers that rely on internationally sourced inputs or finished product importation will face recalibrated landed costs, which could prompt contract renegotiations with suppliers and logistics partners. In anticipation, supply chain leaders are reassessing supplier diversification, nearshoring capacities, and inventory strategies to mitigate exposure to elevated import duties.

Healthcare systems and payers may respond by intensifying cost-containment measures, scrutinizing reimbursement pathways, and accelerating formulary reviews that emphasize total cost of care rather than list price alone. At the same time, manufacturers can pursue alternative mitigations such as localized fill-and-finish facilities, strategic partnerships with domestic contract manufacturing organizations, or bilateral supplier agreements that lock in favorable terms. These operational changes have implications for launch sequencing, pricing strategies, and market access timelines.

Patient access programs and distribution agreements are also likely to be revisited. Specialty pharmacies, hospital procurement teams, and retail networks must adapt to potential shifts in pricing and availability, while clinicians will need clear guidance on therapeutic equivalents and interchangeability where alternative sourcing becomes necessary. Regulators and industry groups will play a role in smoothing transition pathways, emphasizing continuity of care and supply while stakeholders enact commercially viable responses to tariff-driven cost pressures.

Detailed segmentation-driven intelligence uncovering product, indication, channel, end user, regimen, dosing, and patient cohort dynamics that determine market behavior

Segmentation analysis reveals distinct commercial and clinical dynamics across products, indications, channels, end users, regimens, dosing frequencies, and patient cohorts that shape therapeutic positioning and operational priorities. When comparing agents such as brodalumab, ixekizumab, and secukinumab, differences in mechanism nuance, onset of action, and label breadth inform prescriber preference and lifecycle tactics. Indication-specific considerations differentiate use in plaque psoriasis versus psoriatic arthritis, with joint involvement prompting integration with rheumatology pathways and multidisciplinary care coordination.

Distribution strategies vary with channel characteristics: hospital pharmacies focus on formulary negotiation and inpatient continuity; online pharmacies emphasize convenience, adherence support, and specialty fulfillment capabilities; retail pharmacy networks-including chain and independent outlets-drive community-level access and patient counseling. End users show divergent needs: home care settings prioritize simplified administration and remote monitoring, hospitals require reliable inpatient supply and infusion logistics, and specialty clinics depend on integrated nurse-led training and follow-up programs.

Therapeutic regimens also influence adoption patterns. Monotherapy remains central for many patients, while combination approaches incorporating cyclosporine or methotrexate are considered for rapid control or to manage partial responders. Dosing frequency-biweekly versus monthly-affects adherence, clinic throughput, and patient preference, with more frequent dosing sometimes translating to faster clinical response but higher administration touchpoints. Finally, patient-type segmentation between adult and pediatric populations, including adolescent and child subgroups, necessitates tailored safety monitoring, formulation considerations, and support programs to address distinct adherence and caregiver needs.

Comprehensive regional perspectives highlighting access, regulatory, and supply imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific territories

Regional dynamics exert a powerful influence on clinical practice, regulatory approaches, and commercial strategies for IL-17 inhibitors. In the Americas, established payer frameworks, advanced specialty pharmacy ecosystems, and strong clinician adoption patterns create an environment where rapid uptake of novel therapeutics is balanced by intensive payer scrutiny and negotiated access pathways. Market participants focus on value demonstration, outcomes data generation, and integrated care models that support long-term adherence.

Within Europe, the Middle East, and Africa, heterogeneity in regulatory timelines, reimbursement regimes, and healthcare infrastructure requires differentiated entry strategies. Some jurisdictions favor centralized evaluations and health-technology assessments that emphasize comparative effectiveness, while others prioritize cost-containment and tiered access. Manufacturers often deploy region-specific evidence packages, local medical affairs engagement, and targeted pricing approaches to navigate this mosaic.

Asia-Pacific presents a mix of mature and emerging markets with growing demand for advanced biologics, expanding specialty distribution networks, and increasing investment in domestic manufacturing capabilities. Stakeholders in this region concentrate on regulatory harmonization efforts, pathway simplification for biosimilar competition, and public-private partnerships to broaden access. Across all regions, cross-border supply chain resilience, reimbursement alignment, and culturally informed patient support programs remain critical to sustainable adoption and equitable access.

Strategic corporate approaches among manufacturers emphasizing clinical differentiation, lifecycle expansion, and ecosystem partnerships to sustain IL-17 franchise strength

Leading companies in the IL-17 inhibitor space are executing differentiated strategies across clinical development, lifecycle management, and commercial operations. Manufacturers with established products focus on reinforcing clinical value through long-term outcome studies, safety surveillance programs, and head-to-head or real-world comparative analyses. These initiatives support formulary retention and payer negotiations while informing guideline inclusion and specialty society endorsements.

Competitive response strategies include investment in patient support services, digital adherence tools, and nurse-led education to reduce friction at initiation and during maintenance therapy. Business development activity-ranging from licensing deals to localized manufacturing partnerships-enables companies to expand geographic reach and optimize supply chain resiliency. At the same time, firms are exploring label expansions into younger populations and additional immune-mediated indications, subject to robust pediatric and safety data.

Smaller entrants and specialty biotechs concentrate on niche differentiation, focusing on device innovation, novel dosing paradigms, or combination approaches to complement established therapies. Across the board, successful companies balance scientific leadership with pragmatic commercial execution, ensuring that regulatory approvals are matched by reimbursement strategies, distribution partnerships, and provider engagement plans that drive real-world uptake.

Actionable strategic imperatives for manufacturers and stakeholders to secure access, strengthen supply resilience, and drive sustained adoption of IL-17 therapies

Industry leaders should pursue an integrated set of actions to protect patient access, optimize commercial performance, and fortify supply chains amid evolving market dynamics. First, invest in robust real-world evidence programs that quantify outcomes, safety, and adherence across both dermatology and rheumatology practices to support value-based conversations with payers and health systems. Complementary pharmacoeconomic modeling and patient-reported outcomes will strengthen formulary positioning and reimbursement negotiations.

Second, diversify sourcing and manufacturing footprints to reduce exposure to tariff-related disruptions and international supply volatility. Nearshoring fill-and-finish operations, establishing redundant API suppliers, and creating flexible inventory strategies will preserve continuity of care and limit margin pressure. Third, enhance patient support offerings by aligning dosing convenience with digital adherence tools, nurse education, and streamlined home administration programs to improve persistence and satisfaction.

Fourth, tailor regional market entry plans that account for heterogeneous regulatory and reimbursement environments, deploying localized evidence and pricing strategies. Finally, build strategic alliances across stakeholders-payers, providers, specialty pharmacies, and patient advocacy groups-to co-design access solutions and outcomes-based agreements that balance clinical need with economic sustainability. These actions collectively position organizations to respond nimbly to clinical, commercial, and policy shifts.

Transparent mixed-methods research framework combining systematic review, expert primary interviews, and data triangulation to generate actionable IL-17 inhibitor insights

This research synthesis integrates a mixed-methods approach combining systematic literature review, targeted primary research, and triangulation with expert interviews to ensure analytical rigor. The evidence base includes peer-reviewed clinical trials, regulatory filings, guideline statements, and real-world observational studies to capture efficacy, safety, and utilization patterns across therapeutic contexts. Primary research comprised structured interviews with key opinion leaders in dermatology and rheumatology, supply chain executives, specialty pharmacy operators, and payer representatives to contextualize clinical findings within operational realities.

Data triangulation was performed by cross-referencing public regulatory documents with proprietary interview insights and distribution channel intelligence. Segmentation analyses leveraged product characteristics, indication-specific considerations, channel modalities, end user needs, therapeutic regimens, dosing schedules, and patient demographics to construct actionable profiles for stakeholders. Scenario analysis explored tariff-induced supply disruptions, pricing responses, and mitigation strategies without relying on single-source assumptions.

Limitations include the evolving nature of regulatory labels and ongoing post-marketing surveillance, which can affect long-term safety and pediatric use considerations. To mitigate this, the methodology emphasizes transparency in data sources, clear attribution of expert opinion, and a modular framework that permits timely updates as new clinical or policy information becomes available.

Concise synthesis highlighting the intersection of clinical differentiation, supply resilience, and adaptive commercial models that will determine long-term success for IL-17 therapies

In summary, IL-17 inhibitors represent a mature and strategically important therapeutic class for the treatment of plaque psoriasis and psoriatic arthritis, offering compelling clinical benefits alongside operational and commercial complexity. The ongoing evolution of labels, patient cohorts, and dosing paradigms necessitates proactive lifecycle management, focused evidence generation, and adaptable distribution strategies that prioritize continuity of care.

Tariff and supply chain pressures expected to materialize in the near term underscore the need for strategic sourcing and regional manufacturing considerations. At the same time, payer emphasis on outcomes and value creates opportunities for manufacturers that can demonstrate durable clinical benefit and deliver robust patient support. Regional nuances require tailored market access approaches, while segmentation-driven tactics ensure that product, channel, and patient-type strategies are aligned with clinical realities and commercial objectives.

Leaders who integrate clinical evidence, supply resilience, and pragmatic commercialization will be best positioned to maintain and grow access for patients. Continued investment in real-world data, stakeholder engagement, and flexible operational models will determine who captures long-term value in this competitive therapeutic arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IL-17 Inhibitors for Psoriasis Market, by Product

  • 8.1. Brodalumab
  • 8.2. Ixekizumab
  • 8.3. Secukinumab

9. IL-17 Inhibitors for Psoriasis Market, by Indication

  • 9.1. Plaque Psoriasis
  • 9.2. Psoriatic Arthritis

10. IL-17 Inhibitors for Psoriasis Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
    • 10.3.1. Chain
    • 10.3.2. Independent

11. IL-17 Inhibitors for Psoriasis Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. IL-17 Inhibitors for Psoriasis Market, by Therapeutic Regimen

  • 12.1. Combination Therapy
    • 12.1.1. Cyclosporine
    • 12.1.2. Methotrexate
  • 12.2. Monotherapy

13. IL-17 Inhibitors for Psoriasis Market, by Dosing Frequency

  • 13.1. Biweekly
  • 13.2. Monthly

14. IL-17 Inhibitors for Psoriasis Market, by Patient Type

  • 14.1. Adult
  • 14.2. Pediatric
    • 14.2.1. Adolescent
    • 14.2.2. Child

15. IL-17 Inhibitors for Psoriasis Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. IL-17 Inhibitors for Psoriasis Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. IL-17 Inhibitors for Psoriasis Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States IL-17 Inhibitors for Psoriasis Market

19. China IL-17 Inhibitors for Psoriasis Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Almirall, S.A.
  • 20.7. Amgen Inc.
  • 20.8. AstraZeneca PLC
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Bristol Myers Squibb Company
  • 20.11. Celgene Corporation
  • 20.12. Eli Lilly and Company
  • 20.13. Galderma S.A.
  • 20.14. Johnson & Johnson
  • 20.15. LEO Pharma A/S
  • 20.16. Merck & Co., Inc.
  • 20.17. Mylan N.V.
  • 20.18. Novartis AG
  • 20.19. Pfizer Inc.
  • 20.20. Sanofi SA
  • 20.21. Sun Pharmaceutical Industries Ltd.
  • 20.22. Teva Pharmaceutical Industries Ltd.
  • 20.23. UCB S.A.
  • 20.24. Valeant Pharmaceuticals International, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 182. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 189. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 215. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 217. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 222. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 226. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 231. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 233. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)